Holen Sie sich die Stockscreener-App
7.70
2.53%
-0.20
Schlusskurs vom Vortag:
$7.90
Offen:
$7.95
24-Stunden-Volumen:
4.07M
Relative Volume:
1.78
Marktkapitalisierung:
$697.34M
Einnahmen:
$30.91M
Nettoeinkommen (Verlust:
$-209.47M
KGV:
-2.3138
EPS:
-3.3279
Netto-Cashflow:
$-147.13M
1W Leistung:
-0.52%
1M Leistung:
-3.99%
6M Leistung:
+36.77%
1J Leistung:
-14.35%
1-Tages-Spanne:
$7.52
$8.015
1-Wochen-Bereich:
$7.39
$8.40
52-Wochen-Spanne:
$3.43
$10.82
Verastem Inc Stock (VSTM) Company Profile
Firmenname
Verastem Inc
Sektor
Branche
Telefon
(781) 292-4200
Adresse
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
7.70 | 700.96M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Fortgesetzt | BTIG Research | Buy |
| 2026-02-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-16 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-04-10 | Eingeleitet | Jefferies | Buy |
| 2025-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-31 | Bestätigt | BTIG Research | Buy |
| 2024-09-30 | Eingeleitet | Guggenheim | Buy |
| 2023-11-21 | Fortgesetzt | BTIG Research | Buy |
| 2023-09-27 | Eingeleitet | B. Riley Securities | Buy |
| 2023-06-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-07 | Fortgesetzt | Alliance Global Partners | Buy |
| 2022-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-09 | Eingeleitet | Truist | Buy |
| 2021-07-01 | Eingeleitet | Alliance Global Partners | Buy |
| 2021-05-24 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-06-20 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Eingeleitet | BTIG Research | Buy |
| 2018-05-02 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2015-09-29 | Herabstufung | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2015-09-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Herabstufung | Mizuho | Buy → Neutral |
| 2015-09-28 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-05-12 | Bestätigt | UBS | Buy |
| 2015-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-01-23 | Bestätigt | ROTH Capital | Buy |
| 2014-07-08 | Fortgesetzt | Oppenheimer | Perform |
| 2014-02-11 | Eingeleitet | Mizuho | Buy |
Alle ansehen
Verastem Inc Aktie (VSTM) Neueste Nachrichten
Discontinued operations of Verastem, Inc. – HAN:2VSA - TradingView
Verastem, Inc. Actuals & Estimates (HAN:2VSA) - TradingView
Verastem, Inc. (VSTM) stock price, news, quote and history - Yahoo Finance Australia
Verastem, Inc. (VSTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Verastem (VSTM) Shares React to Positive Two-Year Phase 2 RAMP 201 Study Results in Ovarian Cancer - GuruFocus
Half of patients with a specific ovarian cancer mutation stayed on treatment for over a year. - Stock Titan
Cantor Fitzgerald reiterates Overweight on Verastem stock ahead of data By Investing.com - Investing.com Nigeria
Understanding the Setup: (VSTM) and Scalable Risk - Stock Traders Daily
Verastem to present cancer treatment study data at IGCS meeting - Investing.com
Verastem to present cancer treatment study data at IGCS meeting By Investing.com - Investing.com Canada
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting - Business Wire
Form 4 Verastem Inc For: 23 September By Investing.com - Investing.com Canada
Form 4 Verastem Inc For: 23 September - Investing.com India
Verastem CFO Daniel Calkins sells $423 in company stock - Investing.com
Verastem CFO Daniel Calkins sells $423 in company stock By Investing.com - Investing.com South Africa
Verastem (VSTM) CFO Daniel Calkins Sells 55 Shares, Insider Owne - GuruFocus
After selling 55 shares, Verastem (VSTM) CFO Daniel Calkins directly owned 118,014 shares. - Stock Titan
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright - TradingView
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Verastem Inc. Share PriceVSTM, RNS News, Articles, Quotes, & Charts (NASDAQ:VSTM) - Proactive financial news
RBC Capital Keeps Their Buy Rating on Verastem (VSTM) - The Globe and Mail
Verastem Stock Price Forecast. Should You Buy VSTM? - StockInvest.us
Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says - marketscreener.com
Verastem, Inc. (VSTM) Stock Analysis: Unveiling a 94% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Verastem Repeat Insider Selling Not A Positive Indicator - Moomoo
Wolfe Research Initiates Verastem at Outperform - Yahoo Finance
Wolfe Research Maintains Verastem(VSTM.US) With Buy Rating - Moomoo
(VSTM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
H.C. Wainwright reiterates Verastem stock rating on cancer trial data By Investing.com - Investing.com Canada
Verastem Oncology at H.C. Wainwright: dual-track RAS push By Investing.com - Investing.com Canada
VSTM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com
VSTM Reiterated by BTIG -- Price Target Maintained at $18 - GuruFocus
SpaceX Stock Price Today | SPCX Ticker, News, Retail Sentiment - Stocktwits
Verastem at Cantor conference: dual-track growth, big bets By Investing.com - Investing.com India
VSTM: Verastem Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why - The Globe and Mail
Verastem (VSTM) Plans Investor Event to Reveal Preliminary Data on VS-7375 Amid Mixed Market Signals - GuruFocus
A cancer drug’s first broad safety update is set for Oct. 14 from Verastem - Stock Titan
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers - Business Wire
VSTM 8-K FilingsVerastem, Inc. SEC 8-K - Stock Titan
(VSTM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Verastem Oncology to Participate in Upcoming September Investor Conferences - Yahoo! Finance Canada
Verastem Inc. (VSTM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Verastem Inc. (VSTM) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform (NASDAQ:VSTM) - Seeking Alpha
Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views - Yahoo Finance
Verastem (VSTM) Watch: Records a 1.03% Increase to $6.89 on the Day; Technical View - vinanet.vn
Verastem (NASDAQ:VSTM) Shares Down 8.6%Should You Sell? - MarketBeat
Verastem (VSTM) Q2 2026 Earnings Call Transcript - AOL.com
Finanzdaten der Verastem Inc-Aktie (VSTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Verastem Inc-Aktie (VSTM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Calkins Daniel | Chief Financial Officer |
Oct 01 '26 |
Sale |
8.00 |
2,566 |
20,528 |
123,781 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):